Treatment of pancreatic cancer: what can we really predict today?

摘要: Managing pancreatic cancer remains a big challenge due to its worse course and prognosis. However, therapeutic options multimodal strategies are increasing nowadays, including new agents, regimens chemoradiation. Recently, the FOLFIRINOX regimen has been reported be more active than gemcitabine in selected metastatic patients. In this setting, it will of utmost interest guide our choice not only on clinical pathological findings, but also specific biomarkers that predict tumor behavior patient outcome (prognostic markers), benefit from agents or (predictive markers). near future, we have build both interventions research based an accurate patients' selection biomolecular markers. review, aimed highlight discuss some recent results may predict, i.e., preferential diffusion after surgery, like CXCR4, efficacy adjuvant setting as well advanced disease, hENT1. An important effort for translational is thus required validate such markers, while questions concerning tissue availability processing, methodology analysis, design future prospective trials, need addressed.